Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study
Fumihiko Urabe(Jikei University School of Medicine), Hiroki Yamada(Keio University), Keiichiro Miyajima(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Wataru Fukuokaya(Jikei University School of Medicine), Jun Miki(Jikei University School of Medicine), Keiichiro Mori(Jikei University School of Medicine), Masaya Murakami(Jikei University School of Medicine), Takafumi Yanagisawa(Jikei University School of Medicine), Kojiro Tashiro(Jikei University School of Medicine), Sotaro Kayano(Jikei University Kashiwa hospital), Shunsuke Tsuzuki(Jikei University School of Medicine), Yu Imai(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Hidetsugu Takahashi(Jikei University School of Medicine), Katsuki Muramoto(Jikei University School of Medicine), Tatsuya Shimomura(Jikei University School of Medicine), Kentaro Yoshihara(Jikei University School of Medicine), Taro Igarashi(Jikei University School of Medicine), Kota Katsumi(Jikei University School of Medicine)
Cited by 20
Related Papers
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282
Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
|Clinical Cancer Research|2019|129
Exploiting the message from cancer: the diagnostic value of extracellular vesicles for clinical applications
|Experimental & Molecular Medicine|2019|112
Extracellular vesicles in the development of organ‐specific metastasis
|Journal of Extracellular Vesicles|2021|101